pipeline-prospector-insert-v1
X

Find Immunology Drugs in Phase I Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JSP191

            Therapeutic Area: Immunology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Abingworth

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 09, 2020

            Details:

            Funds will be used to advance JSP191, the first clinical-stage antibody designed for use as a single and combination conditioning agent in patients undergoing curative allogeneic hematopoietic cell transplan

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-450,Methotrexate

            Therapeutic Area: Immunology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            ATI-450 resulted in inhibition of TNFα, IL1β, IL8, and IL6, was generally well-tolerated at all doses tested in the trial; had no significant food effect or drug-drug interaction with methotrexate.